Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer

NCT01026337 · clinicaltrials.gov ↗

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma
Stage III Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions

GENETIC: mutation analysis
OTHER: pharmacological study
PROCEDURE: dynamic contrast-enhanced magnetic resonance imaging
DRUG: sunitinib malate
OTHER: immunohistochemistry staining method
OTHER: laboratory biomarker analysis

Sponsor

Abramson Cancer Center at Penn Medicine